Skip to main content

All Articles

For the first time, an adjuvant treatment has led to a survival benefit in clear cell renal cell carcinoma (ccRCC). Data from the multicenter phase 3 KEYNOTE-564 study demonstrate that adjuvant pembrolizumab led to a 38% lower risk of death compared with placebo among patients with ccRCC who had a high risk of recurrence after surgery. The findings were presented by Toni K. Choueiri, MD, at the 2024 ASCO Genitourinary Cancers Symposium. Read More ›

A subcutaneous (SC) form of nivolumab was just as effective as IV nivolumab on progression-free survival (PFS) in patients with previously treated advanced renal cell carcinoma (ccRCC), with no increase in hypersensitivity reactions. The SC form is more convenient and less time consuming to administer, with an average administration time of 5 minutes or less. Read More ›

An important and inspiring documentary on Dr Carl June’s quest to cure cancer, CAR T-cell therapy, and his first pediatric patient. Read More ›

In 2023, much research has been conducted on the treatment of biliary tract cancer (BTC), with an emphasis on novel targeted therapies and combination strategies. Important advances in treatment for patients with BTC were presented at society conferences such as the American Society of Clinical Oncology (ASCO), ASCO GI, and European Society for Medical Oncology. Read More ›

In the KEYNOTE-966 study, pembrolizumab was added to gemcitabine/cisplatin to assess outcomes in patients with advanced biliary tract cancer. Read More ›

This post-hoc analysis of the ABC-01, -02, and -03 clinical trials provides reference survival data for patients with advanced extrahepatic cholangiocarcinoma treated with first-line gemcitabine/cisplatin chemotherapy. Read More ›

Investigators pooled data from 3 trials to evaluate tinengotinib in patients with advanced, refractory/relapsed cholangiocarcinoma who previously received an FGFR inhibitor. Read More ›

Researchers evaluated KLF5 expression and its inhibition in cholangiocarcinoma using clustered regularly interspaced short palindromic repeats technology. Read More ›

In this ongoing phase 2 study, the efficacy of SHR-1316 plus IBI310 is being evaluated in patients with advanced intrahepatic cholangiocarcinoma after inadequate response to first-line therapy. Read More ›

Dr Mahmood presented results from the largest multi-institutional review of efficacy outcomes following targeted agents in patients with cholangiocarcinoma. Read More ›

Page 2 of 305